z-logo
open-access-imgOpen Access
The Correlation Between the Serum Squamous Carcinoma Antigen and the Prognosis of Recurrent Cervical Squamous Carcinoma
Author(s) -
Wang Yan,
Cui Tong,
Du Lili,
Xu Xiaoqin,
Tian Baoguo,
Sun Ting,
Han Cunzhi,
Zhao Xianwen,
Jing Jiexian
Publication year - 2017
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22020
Subject(s) - medicine , gastroenterology , carcinoma , multivariate analysis
Background To explore the relationship of the serum squamous cell carcinoma antigen ( SCC ‐Ag) with the pathologic characteristics, occurrence, and prognosis of cervical squamous carcinoma. Methods The enzyme‐linked immunosorbent assay ( ELISA ) method was used to determine the serum SCC ‐Ag levels for the patients, which included 424 pretreatment patients and 500 cases after treatment. Results (a) Pretreatment SCC ‐Ag levels of patients were related to clinical stages, lymphatic metastasis, and myometrial invasion, (b) within a median follow‐up of 54 months, 180 recurrences (36%) and 102 disease‐associated deaths (20.4%) were recorded, 161 recurrent patients showed elevated SCC ‐Ag levels (161/180, 89.4%), and 60 of them (37.3%) had a significant increase in SCC ‐Ag serum levels before clinical manifestation of relapse. The lead time ranged between 1 and 5 months (median: 2.3 months). The total survival rates were 23.4% and 17.8% for 3‐year and 5‐year period, respectively, and (c) clinical stages, the site of recurrence, and SCC ‐Ag levels after treatment were closely related with recurrent patients' survival time ( P < 0.01~<0.005). Multivariate analysis indicated that the clinical stages and SCC ‐Ag levels of recurrent patients were independent prognostic factors ( P < 0.05˜0.01). Conclusion Serum SCC ‐Ag level was an important predictor for the cervical squamous carcinoma recurrence and prognosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here